Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Zoledronate in Preventing Bone Loss in Postmenopausal Women Who Are Receiving Letrozole for Stage I, Stage II, or Stage IIIA Breast Cancer

This study has been completed.
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Alliance for Clinical Trials in Oncology
ClinicalTrials.gov Identifier:
NCT00107263
First received: April 5, 2005
Last updated: August 12, 2016
Last verified: August 2016